Shareholder meetings, this week and ahead.
Every upcoming AGM and special meeting at a rated U.S. public issuer. Record dates, nomination deadlines, board grades, and non-standard ballot items shown inline. Defaults to the next 14 days; expand the window from the filter bar.
Browse all upcoming meetings by month
Tuesday, July 21, 2026
1 meeting| Company | Performance | Ballot summary |
|---|---|---|
| GENESCO INCContested | Board: C 1Y TSR: +48.1% | Election of nine directors (including two shareholder nominees), a non-binding advisory 'Say on Pay' vote on executive compensation, approval of an amended equity incentive plan increasing the share reserve, and ratification of Deloitte as the company’s independent registered public accounting firm. |
Wednesday, July 22, 2026
3 meetings| Company | Performance | Ballot summary |
|---|---|---|
| CONSTELLATION BRANDS INC | Board: C- 1Y TSR: -17.6% | Elect twelve directors; ratify the selection of KPMG LLP as independent registered public accounting firm; approve, on an advisory basis, the compensation of the Company’s named executive officers; approve the amendment and restatement of the Company’s Long‑Term Stock Incentive Plan; and transact any other properly presented business. |
| MCKESSON CORP | Board: B 1Y TSR: +10.4% | Elect 11 director nominees; Ratify Deloitte & Touche LLP as independent auditor for FY2027; Advisory (non-binding) vote on executive compensation (say-on-pay). |
| SAMSARA INC | Board: C+ 1Y TSR: -10.9% | Elect eight directors; ratify Deloitte & Touche LLP as independent registered public accounting firm for fiscal year ending January 30, 2027; and approve, on a non-binding advisory basis, the compensation of the company’s named executive officers. |
Thursday, July 23, 2026
2 meetings| Company | Performance | Ballot summary |
|---|---|---|
| BROWN FORMAN CORP | Board: C- 1Y TSR: -6.2% | Stockholders will vote to elect eleven directors, approve on a non-binding advisory basis the compensation of the company’s named executive officers (say-on-pay), and ratify Ernst & Young LLP as the independent registered public accounting firm for fiscal 2027. |
| JAZZ PHARMACEUTICALS PLC | Board: B- 1Y TSR: +109.1% | Election of three directors; Ratification and remuneration authorization for KPMG as auditor; Non-binding advisory vote on executive compensation (say-on-pay); Approval to grant the board authority to allot and issue ordinary shares; Special resolution to allow board to allot and issue ordinary shares for cash without offering to existing shareholders (pre-emption opt-out) up to ~20% of issued share capital for 18 months; Adjournment proposal to solicit additional proxies if insufficient votes for Proposals 4 or 5. |
Tuesday, July 28, 2026
2 meetings| Company | Performance | Ballot summary |
|---|---|---|
| LINDE PLC | Board: A- 1Y TSR: +13.0% | Shareholders will vote to elect nine directors; ratify PricewaterhouseCoopers as auditor and authorize the Board to determine its remuneration; approve, on an advisory basis, named executive officer compensation; determine the price range for re-allotment of treasury shares under Irish law; and consider a shareholder proposal requesting a report on the Company’s renewable electricity procurement strategy. |
| SEER INCContested | Board: C- 1Y TSR: -11.4% | Election of seven directors; ratification of Deloitte & Touche LLP as independent registered public accounting firm for fiscal 2026; non-binding advisory vote to approve named executive officer compensation (say-on-pay); ratification of the Tax Benefit Preservation Plan through February 25, 2029 (unless earlier terminated); and transacting other business as may properly come before the meeting. |
Thursday, July 30, 2026
3 meetings| Company | Performance | Ballot summary |
|---|---|---|
| COREBRIDGE FINANCIAL INC | Board: C- 1Y TSR: -12.2% | Stockholders of Corebridge and Equitable are being asked to approve the Merger Agreement (each company), to cast non-binding advisory votes on transaction-related executive compensation (each company), to adopt Corebridge’s 2026 Employee Stock Purchase Plan, and to approve adjournment authority (each company) to solicit additional proxies if necessary. |
| EQUITABLE HOLDINGS INC | Board: C+ 1Y TSR: -11.1% | Corebridge and Equitable stockholders will vote on merger adoption proposals, non-binding advisory votes on transaction-related executive compensation, a Corebridge employee stock purchase plan adoption, and adjournment proposals to solicit additional proxies if needed. |
| RALPH LAUREN CORP | Board: B 1Y TSR: +38.1% | Stockholders will vote to elect twelve directors, ratify Ernst & Young LLP as the independent registered public accounting firm for fiscal 2027, and cast an advisory (non-binding) vote to approve the compensation of the named executive officers and the Company’s compensation philosophy, policies, and practices. |
Friday, July 31, 2026
2 meetings| Company | Performance | Ballot summary |
|---|---|---|
| NANO DIMENSION LTDContested | Board: C- 1Y TSR: -5.6% | One management-sponsored non-binding advisory vote on continuation of the Board’s strategic alternatives review and six shareholder-sponsored proposals from Murchinson to (1) declassify the Board and require annual director elections, (2) prohibit adoption of a poison pill without shareholder approval, (3) require shareholder approval for major transactions (limited duration), (4) remove three named directors and any directors appointed after the Demand Date, and (5) appoint three nominated directors contingent on removals. |
| STERIS PLC | Board: C+ 1Y TSR: -7.0% | Election of nine directors; ratification of Ernst & Young LLP as the independent registered public accounting firm for fiscal 2027; appointment of Ernst & Young Chartered Accountants as the Company’s Irish statutory auditor and authorization for the Board/Audit Committee to determine that auditor’s remuneration; advisory (non-binding) Say-on-Pay vote on named executive officer compensation; renewal of the Board’s authority to issue shares (up to ~20% of issued share capital) and to opt out of statutory pre-emption rights (up to ~20%, with >10% reserved for acquisitions/specified capital investments); and authorization for proxy holders to vote on any other business properly brought before the meeting. |